Skip to main content

DBV Technologies S.A.

DBVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001613780

In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.

Other share classesDBVTF

Q4 2021 vs. Q3 2021

How the institutions holding DBV Technologies S.A. changed between Q3 2021 and Q4 2021.

All holders in Q4 2021All holders in Q3 2021

13F holders of DBVT: Q3 2021 compared with Q4 2021
MeasureQ3 2021Q4 2021Change
Holders5141−10
Shares36.4M21.3M−15.1M (−41.4%)
Value$179.8M$34.7M−$145.1M (−80.7%)

New holders (8)

Institutions that held DBV Technologies S.A. at the end of Q4 2021 but not at the end of Q3 2021.

Institutions new to DBVT in Q4 2021
InstitutionSharesValue% of portfolio
Credit Suisse AG77,067$123.0K0.00%
Virtu Financial LLC53,242$85.0K0.01%
Envestnet Asset Management Inc26,663$43.0K0.00%
Two Sigma Securities, LLC25,229$40.0K0.01%
FNY Investment Advisers, LLC20,000$32.0K0.02%
Tower Research Capital LLC (TRC)355$1.00K0.00%
Parallel Advisors, LLC428$1.00K0.00%
Citigroup Inc61$00.00%

Sold out (18)

Institutions that held DBV Technologies S.A. at the end of Q3 2021 and filed for Q4 2021 without it.